A Phase 3 interventional study of Placebo and Brexpiprazole in Post-traumatic Stress Disorder and PTSD, sponsored by H. Lundbeck A/S. Terminated at 59 sites in 9 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-03-13.
Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States — 341 open to participants now, 404 under way, 18 of them phase 3. Stress Disorders, Post-Traumatic · United States.
Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, this one is the 76th largest by enrollment of the 1,491 interventional ones that give a count, is one of 70 that started in 2013, is one of 64 in phase 3, and was the 523rd registered.
2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →341 of the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–55
Summit Hyperbarics and Wellness · Sites in United States
Ages 18–75
Anthony Vesco · Sites in United States
Ages 8–18
Transcend Therapeutics · Sites in United States
Ages 18+
COMPASS Pathways · Sites in United States, Canada
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,664 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 132 · Phase 2 234 · Phase 3 95 · Phase 4 90
First in 1991; this study’s year is marked. 70 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 417 is above the median of 69 across 2,201 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 65 across the 1,491 interventional studies, 107 across the 165 observational. Of the 1,135 that completed or were terminated, 491 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
98 of 1,664 have an industry lead sponsor. The 10 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
H. Lundbeck A/S has 2 studies filed under Stress Disorders, Post-Traumatic — fewer than ten, so there is no comparison to draw.
154 of the studies in Stress Disorders, Post-Traumatic with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06117306Phase 3Healing BreakthroughMDMA-assisted Massed Prolonged Exposure for PTSD | 2027-03 |
| NCT04877093Phase 3Wake Forest University Health SciencesRepurposing Low-Dose Clonidine for PTSD in Veterans | 2027-03-31 |
| NCT06273527Phase 3University of California, San DiegoEnhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33) | 2027-06-01 |
| NCT07217795University of Rhode IslandRecovery Through Inhibitory Learning, Self-Efficacy Building, Problem Solving, and Community Building | 2026-11 |
| NCT04585685Christal L BadourHealthy Recovery After Trauma Study | 2026-11 |
Add all 154 to your calendar (.ics) → With an account.
Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy of brexpiprazole as adjunctive treatment to paroxetine (PAR) or sertraline (SER) on PTSD symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo adjunct to open-label treatment with a commercially available approved treatment for PTSD (PAR/SER)
Drug: Placebo
Brexpiprazole adjunct to open-label treatment with a commercially available approved treatment for PTSD (PAR/SER). Brexpiprazole dosing was 1mg/day for one week, followed by 2mg/day for 3 weeks. Thereafter the dose was flexible and could be adjusted from 1 to 3 mg/day.
Drug: Brexpiprazole
Once daily, tablets, orally
1 to 3 mg/day, once daily dose, tablets, orally
PTSD Symptoms Using CAPS-2 Total Score
Clinician-Administered PTSD Scale Part 2 (CAPS-2): 17 items in criteria B, C and D (Corresponding to CAPS-2) will be administered to provide a total score. They are rated on a 5 point scale for frequency from 0 (never or none) to 4 (daily or almost every day), and intensity from 0 (none) to 4 (extreme). The sum of the 17 items gives a toal score ranging from 0 to 136, with a higher score indicating greater symptom severity.
Time frame: Period 2: Baseline to Week 12 (of randomized period)
Global Clinical Impression Severity of Illness (CGI-S) Score
Clinical Global Impression - Severity of Illness (CGI-S) The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).
Time frame: Period 2: Baseline to Week 12 (of randomized period)
417 patients were enrolled to the study and 413 patients received open-label treatment with a commercially available treatment for PTSD (PAR/SER) in Period 1. Only 40 patients were randomized to Period 2, the randomized period, before the study was terminated; 190 patients entered Period 3. Data are only reported for the randomized period.
| Milestone | Period 1 Placebo and PAR/SER | Period 2 Placebo and PAR/SER (Randomized Period) | Period 2 Brexpiprazole and PAR/SER (Randomized Period) | Period 3 Placebo and PAR/SER |
|---|---|---|---|---|
| Started | 417 | 0 | 0 | 0 |
| Completed | 231 | 0 | 0 | 0 |
| Not completed | 186 | 0 | 0 | 0 |
| Withdrew: Adverse event | 24 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 4 | 0 | 0 | 0 |
| Withdrew: Non-compliance with imp | 6 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 12 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 21 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 40 | 0 | 0 | 0 |
| Withdrew: Administrative or other reason | 75 | 0 | 0 | 0 |
| Withdrew: Withdrawal of consent before treatment | 4 | 0 | 0 | 0 |
| Milestone | Period 1 Placebo and PAR/SER | Period 2 Placebo and PAR/SER (Randomized Period) | Period 2 Brexpiprazole and PAR/SER (Randomized Period) | Period 3 Placebo and PAR/SER |
|---|---|---|---|---|
| Started | 0 | 17 | 23 | 0 |
| Completed | 0 | 12 | 14 | 0 |
| Not completed | 0 | 5 | 9 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
| Withdrew: Administrative or other reason | 0 | 5 | 7 | 0 |
| Milestone | Period 1 Placebo and PAR/SER | Period 2 Placebo and PAR/SER (Randomized Period) | Period 2 Brexpiprazole and PAR/SER (Randomized Period) | Period 3 Placebo and PAR/SER |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 190 |
| Completed | 0 | 0 | 0 | 119 |
| Not completed | 0 | 0 | 0 | 71 |
| Withdrew: Adverse event | 0 | 0 | 0 | 7 |
| Withdrew: Non-compliance with imp | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 6 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 9 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 5 |
| Withdrew: Administrative or other reason | 0 | 0 | 0 | 43 |
Clinician-Administered PTSD Scale Part 2 (CAPS-2): 17 items in criteria B, C and D (Corresponding to CAPS-2) will be administered to provide a total score. They are rated on a 5 point scale for frequency from 0 (never or none) to 4 (daily or almost every day), and intensity from 0 (none) to 4 (extreme). The sum of the 17 items gives a toal score ranging from 0 to 136, with a higher score indicating greater symptom severity.
| Score | Period 2 Absolute Mean at Baseline; Placebo and PAR/SER | Period 2 Absolute Mean at Baseline; Brexpiprazole and PAR/SER | Period 2 Absolute Mean at Week 12; Placebo and PAR/SER | Period 2 Absolute Mean at Week 12; Brexpiprazole and PAR/SER |
|---|---|---|---|---|
| PTSD Symptoms Using CAPS-2 Total Score | 82.82 ± 12.94 | 83.43 ± 13.12 | 69.67 ± 20.26 | 69.18 ± 18.17 |
Clinical Global Impression - Severity of Illness (CGI-S) The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).
| Score | Period 2 Absolute Mean at Baseline; Placebo and PAR/SER | Period 2 Absolute Mean at Baseline; Brexpiprazole and PAR/SER | Period 2 Absolute Mean at Week 12; Placebo and PAR/SER | Period 2 Absolute Mean at Week 12; Brexpiprazole and PAR/SER |
|---|---|---|---|---|
| Global Clinical Impression Severity of Illness (CGI-S) Score | 4.24 ± 0.83 | 4.54 ± 0.73 | 3.73 ± 1.10 | 3.94 ± 0.83 |
Collected over Period 2: Baseline to Week 16 (randomized period). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brexpiprazole + PAR/SER (Randomized Period) | — | 0/23 (0%) | 3/23 (13%) |
| Placebo + PAR/SER (Randomized Period) | — | 0/17 (0%) | 8/17 (47.1%) |
| Event | Brexpiprazole + PAR/SER (Randomized Period) | Placebo + PAR/SER (Randomized Period) |
|---|---|---|
| Accidental overdoseInjury, poisoning and procedural complications | 2/23 | 1/17 |
| ConjunctivitisEye disorders | 0/23 | 1/17 |
| GastroenteritisInfections and infestations | 0/23 | 1/17 |
| PharyngitisInfections and infestations | 0/23 | 1/17 |
| Upper respiratory tract infectionInfections and infestations | 0/23 | 1/17 |
| Tendon ruptureInjury, poisoning and procedural complications | 0/23 | 1/17 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 0/23 | 1/17 |
| Back painMusculoskeletal and connective tissue disorders | 1/23 | 1/17 |
| Disturbance in attentionNervous system disorders | 0/23 | 1/17 |
| GalactorrhoeaReproductive system and breast disorders | 0/23 | 1/17 |
The all-patients-treated set (APTS) comprises all randomized patients who took at least one dose of brexpiprazole or placebo.
| Age, Continuous(years) | Period 2 Placebo and PAR/SER (Randomized Period) | Period 2 Brexpiprazole and PAR/SER (Randomized Period) | Total |
|---|---|---|---|
| Mean | 42.9 ± 11.8 | 47.6 ± 10.4 | 45.6 ± 11.1 |
| Sex: Female, Male(Participants) | Period 2 Placebo and PAR/SER (Randomized Period) | Period 2 Brexpiprazole and PAR/SER (Randomized Period) | Total |
|---|---|---|---|
| Female | 10 | 11 | 21 |
| Male | 7 | 12 | 19 |
The record gives a start of Dec 2013, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Stress Disorders, Post-Traumatic →